# Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain

> **NCT01049373** · PHASE3 · COMPLETED · sponsor: **Pascoe Pharmazeutische Praeparate GmbH** · enrollment: 221 (actual)

## Conditions studied

- Low Back Pain

## Interventions

- **DRUG:** HDC
- **DRUG:** Placebo solution

## Key facts

- **NCT ID:** NCT01049373
- **Lead sponsor:** Pascoe Pharmazeutische Praeparate GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2012-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01049373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01049373, "Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01049373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*